Milestone Pharmaceuticals is trading at $0.70, down 7.95%, after the company disclosed a Nasdaq minimum-bid-price deficiency notice. - Nasdaq cited a share price below $1.00 for 30 consecutive business days; the company has until April 21, 2027, to regain compliance. - The notice has no immediate effect on its listing. - Available reporting does not confirm the notice directly caused the pre-market decline. No pre-market volume data was available in the sources reviewed.